文献速递鼻科

冷冻消融后鼻神经治疗鼻炎:前瞻性多中心研究

Cryosurgical ablation for treatment of rhinitis: A prospective multicenter study.
PubMed 文献 · Laryngoscope · 2019-09-30

这项前瞻性单臂多中心研究纳入98例慢性过敏性及非过敏性鼻炎成人患者,在局麻下门诊行后鼻神经冷冻消融。

要点

  • 后鼻神经冷冻消融可显著改善慢性鼻炎鼻部症状并持续至9个月。
  • 过敏性及非过敏性鼻炎亚组均改善,组间改善程度相当。
  • 治疗安全性可接受,常见不良反应包括头痛、鼻出血和鼻窦炎。

核心结论

  • 后鼻神经冷冻消融治疗慢性鼻炎安全,可缓解鼻部症状并改善生活质量。

研究设计与样本

  • 前瞻性单臂多中心研究,纳入6个美国中心的98例慢性过敏性及非过敏性鼻炎成人患者。
  • 在局麻下门诊使用手持设备行后鼻神经冷冻消融,治疗前3天及研究期间停用鼻内异丙托溴铵。

主要发现

  • rTNSS从基线6.1±1.9显著改善至1个月2.9±1.9、3个月3.0±2.3、6个月3.0±2.1、9个月3.0±2.4(均P<0.001)。
  • 鼻塞和流涕子评分在所有时间点均显著改善(P<0.001)。
  • 过敏性和非过敏性鼻炎亚组均改善(P<0.001),组间改善程度相当。
  • RQLQ从基线3.0±1.0显著改善至3个月1.5±1.0(P<0.001),所有子领域均改善。
  • 54例基线使用鼻内药物的患者中19例(35.2%)能够停用。

关键数值与推荐

  • 98例手术(100%)成功完成。
  • 证据等级为4级。

临床怎么用

  • 对于慢性过敏性及非过敏性鼻炎患者,可考虑在局麻门诊行后鼻神经冷冻消融以改善鼻部症状和生活质量。
  • 术后需关注头痛、鼻出血和鼻窦炎等不良反应。

局限性

  • 单臂设计,无对照组。
  • 证据等级为4级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the efficacy and safety of cryoablation of the posterior nasal nerve (PNN) for treatment of chronic rhinitis. METHODS: This was a prospective single-arm trial of 98 adult patients at six U.S. centers with chronic allergic and nonallergic rhinitis. PNN cryoablation was performed in-office under local anesthesia using a handheld device. Patients discontinued use of intranasal ipratropium 3 days prior to treatment and throughout the study period. Reflective Total Nasal Symptom Score (rTNSS) was measured at pretreatment baseline and posttreatment at 1 month, 3 months, 6 months, and 9 months. The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was completed at pretreatment and 3 months posttreatment. Adverse effects and postprocedure medication usage were recorded. RESULTS: Ninety-eight procedures (100%) were successfully completed. rTNSS significantly improved over pretreatment baseline (6.1 ± 1.9) at 1 month (2.9 ± 1.9, P < 0.001), 3 months (3.0 ± 2.3, P < 0.001), 6 months (3.0 ± 2.1, P < 0.001), and 9 months (3.0 ± 2.4, P < 0.001) postprocedure. Nasal congestion and rhinorrhea subscores improved significantly at all time points (P < 0.001). Both allergic and nonallergic rhinitis subcohorts showed improvement (P < 0.001), with a comparable degree of improvement between groups. RQLQ significantly improved over pretreatment baseline (3.0 ± 1.0) at 3 months (1.5 ± 1.0, P < 0.001), and all RQLQ subdomains demonstrated improvement. Of 54 patients using intranasal medication at baseline, 19 (35.2%) were able to discontinue use. Twenty-nine adverse effects were reported, including headache, epistaxis, and sinusitis. CONCLUSION: Cryoablation of the PNN for chronic rhinitis is safe and can result in relief of nasal symptoms and improvements in quality of life. LEVEL OF EVIDENCE: 4 Laryngoscope, 130: 1877-1884, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Chang MT, Song S, Hwang PH, et al. Cryosurgical ablation for treatment of rhinitis: A prospective multicenter study. Laryngoscope. 2019. PMID: 31566744. doi:10.1002/lary.28301

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。